https://mindmedicinelaw.com/briefing/psychedelics-for-ptsd-efficacy-and-risks-in-focus-20260805-29235The Psychedelic Journalen2026-08-05T15:05:07.005650+00:00Psychedelics for PTSD: Efficacy and Risks in Focuspsychedelics, PTSD treatment, systematic review, clinical guidelines, MDMA, psilocybin, neuroplasticity, therapeutic use, policy implications, clinical trialshttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-salivary-glands-new-research-insights-20260804-29256The Psychedelic Journalen2026-08-05T22:04:48.654577+00:00Ketamine's Impact on Salivary Glands: New Research Insightsketamine, salivary glands, redox balance, inflammatory homeostasis, recreational drug use, clinical guidelines, public health, biochemical impacts, therapeutic use, safety profilehttps://mindmedicinelaw.com/briefing/iv-ketamine-for-crps-insights-from-recent-meta-analysis-20260804-29244The Psychedelic Journalen2026-08-05T15:05:33.620143+00:00IV Ketamine for CRPS: Insights from Recent Meta-Analysisketamine, CRPS, pain management, systematic review, meta-analysis, predictors of response, clinical guidelines, neuropathic pain, analgesic properties, personalized treatmenthttps://mindmedicinelaw.com/briefing/entropy-neurodynamics-trp-8803-trial-implications-for-psychedelic-therapy-20260804-29277The Psychedelic Journalen2026-08-05T15:05:24.302967+00:00Entropy Neurodynamics' TRP-8803 Trial: Implications for Psychedelic TherapyTRP-8803, Entropy Neurodynamics, psychedelic therapy, clinical trials, mental health, serotonin receptors, regulatory frameworks, FDA, EMA, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-evidence-outpaces-clinical-guidelines-in-2026-20260804-29275The Psychedelic Journalen2026-08-05T15:04:42.153440+00:00Psilocybin Evidence Outpaces Clinical Guidelines in 2026psilocybin research, clinical guidelines, psychedelic therapy, mental health treatment, FDA, evidence-based medicine, therapeutic potential, policy update, healthcare integration, neuroplasticityhttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-new-insights-into-motivation-20260803-29370The Psychedelic Journalen2026-08-05T22:05:12.806283+00:00GABAergic Cells in Zona Incerta: New Insights into MotivationGABAergic cells, zona incerta, motivation modulation, neuroscience, treatment-resistant deficits, brain functionhttps://mindmedicinelaw.com/briefing/patient-perspectives-on-implanted-neurotech-for-depression-20260803-29372The Psychedelic Journalen2026-08-05T22:05:04.618550+00:00Patient Perspectives on Implanted Neurotech for Depressionimplanted neurotechnology, treatment-refractory depression, patient-centered design, neurotechnology adoption, therapy delivery flexibility, implant approach, deep brain stimulation, neurotechnology ethics, patient decision-making, neurotechnology innovationhttps://mindmedicinelaw.com/briefing/gabaergic-cells-in-zona-incerta-new-avenues-for-motivation-20260803-29376The Psychedelic Journalen2026-08-05T22:04:55.557335+00:00GABAergic Cells in Zona Incerta: New Avenues for MotivationGABAergic cells, zona incerta, motivation modulation, neuroscience, mental health treatment, treatment-resistant deficitshttps://mindmedicinelaw.com/briefing/distinct-brain-activity-from-psychedelics-in-rat-studies-20260803-29329The Psychedelic Journalen2026-08-05T22:04:28.559639+00:00Distinct Brain Activity from Psychedelics in Rat Studiesserotonergic psychedelics, brain activity patterns, neuropsychiatric disorders, psilocybin, LSD, 2C-B, metabolic activity, therapeutic applications, clinical research, psychedelic therapieshttps://mindmedicinelaw.com/briefing/fda-s-new-guidance-on-psychedelic-trials-implications-and-impact-20260803-29274The Psychedelic Journalen2026-08-05T15:04:32.759540+00:00FDA's New Guidance on Psychedelic Trials: Implications and ImpactFDA guidance, psychedelic trials, clinical research, psilocybin, MDMA, Schedule I drugs, therapeutic benefits, mental health, regulatory pathways, investment in psychedelicshttps://mindmedicinelaw.com/briefing/evolving-drug-detection-strategies-forensic-and-clinical-impacts-20260803-28905The Psychedelic Journalen2026-08-04T15:07:11.159539+00:00Evolving Drug Detection Strategies: Forensic and Clinical Impactsdrug detection methods, new psychoactive substances, forensic applications, clinical settings, chromatographic methods, mass spectrometry, electrochemical platforms, biosensor technologies, field screening, public health monitoringhttps://mindmedicinelaw.com/briefing/mechanisms-of-psychedelic-therapy-new-approaches-explored-20260803-28904The Psychedelic Journalen2026-08-04T15:06:53.233459+00:00Mechanisms of Psychedelic Therapy: New Approaches Exploredpsychedelic therapy, low-dose psychedelics, breathwork, vagus nerve stimulation, serotonergic neurochemistry, psychiatric conditions, clinical trials, neurochemical plasticity, autonomic recalibration, tailored interventionshttps://mindmedicinelaw.com/briefing/5-meo-dmt-cbt-in-alcohol-use-disorder-uk-trial-insights-20260803-28934The Psychedelic Journalen2026-08-04T15:06:41.650403+00:005-MeO-DMT & CBT in Alcohol Use Disorder: UK Trial Insights5-MeO-DMT, cognitive behavioral therapy, alcohol use disorder, psychedelic-assisted therapy, psychological change, clinical trial, addiction treatment, emotional regulation, self-awareness, London UKhttps://mindmedicinelaw.com/briefing/psychological-control-reserve-model-implications-for-therapy-20260802-28935The Psychedelic Journalen2026-08-04T15:07:20.703470+00:00Psychological Control & Reserve Model: Implications for Therapypsychological control, psychological reserve, psychotherapy, psychedelic-assisted therapy, cognitive control, emotional regulation, therapeutic frameworks, psychological resiliencehttps://mindmedicinelaw.com/briefing/psychedelic-therapy-for-ptsd-insights-from-a-us-study-20260730-29276The Psychedelic Journalen2026-08-05T15:04:55.456523+00:00Psychedelic Therapy for PTSD: Insights from a US Studypsychedelic therapy, PTSD treatment, veterans, mental health, clinical trials, policy implications, neuroplasticity, psychedelics, MDMA, psilocybinhttps://mindmedicinelaw.com/briefing/ketamine-hair-analysis-new-method-validated-for-clinical-use-20260729-29005The Psychedelic Journalen2026-08-04T22:05:41.867679+00:00Ketamine Hair Analysis: New Method Validated for Clinical Useketamine hair analysis, enzyme immunoassay, LC-MS/MS, drug monitoring, clinical trials, pharmacokinetics, therapeutic ketamine use, non-invasive drug testing, long-term drug assessment, psychedelic therapieshttps://mindmedicinelaw.com/briefing/advancements-in-ketamine-analysis-hair-testing-breakthrough-20260729-28955The Psychedelic Journalen2026-08-04T15:07:29.805465+00:00Advancements in Ketamine Analysis: Hair Testing Breakthroughketamine analysis, hair testing, enzyme immunoassay, LC-MS/MS, clinical trials, forensic investigations, drug monitoring, compliance tracking, research methods, drug detectionhttps://mindmedicinelaw.com/briefing/neuroimmune-pathways-in-ketamine-and-psychedelics-20260728-29267The Psychedelic Journalen2026-08-05T22:04:38.817309+00:00Neuroimmune Pathways in Ketamine and Psychedelicsneuroimmune signaling, ketamine, psychedelics, rapid antidepressant effects, depression treatment, clinical trials, drug development, mental health, neuroscience, policy implicationshttps://mindmedicinelaw.com/briefing/standardizing-integration-in-psychedelic-therapy-trials-20260726-28929The Psychedelic Journalen2026-08-04T15:07:02.050189+00:00Standardizing Integration in Psychedelic Therapy Trialspsychedelic-assisted therapy, integration practices, clinical trials, standardized protocols, psilocybin, participant safety, therapist qualifications, cross-trial comparisons, mental health treatment, phase III trialshttps://mindmedicinelaw.com/briefing/mushroom-producing-amatoxins-and-psilocybin-implications-20260722-29150The Psychedelic Journalen2026-08-04T22:05:31.115096+00:00Mushroom Producing Amatoxins and Psilocybin: Implicationsamatoxins, psilocybin, mushroom species, toxicology, therapeutic use, public health, biochemical pathways, regulation, safety protocols, genetic testing